P4‐125: Cognitive Event‐Related Potentials Used As Biomarkers in Pleodial‐I Study: First Evidence of a Neurophysiological Effect of PXT864 in Mild Alzheimer’s Disease Patients Article Swipe

PDF

Karim Bennys , Raphaël Haddad , Catherine Scart Grès , Peter A. Schmitt , Jacques Touchon ·

YOU? · · 2016 · Open Access · · DOI: https://doi.org/10.1016/j.jalz.2016.06.2216

Cognitive event related potential (ERP) is a usefull biomarker for the diagnosis of Alzheimer's Disease (AD), even from the preclinical stage. We report here the use of ERP in a phase IIa clinical study to explore in mild AD patients the symptomatic effect of PXT864, an under-development fixed combination of low doses of acamprosate and baclofen, which has shown multiple reversions of pathological alteration in cellular and animal models of AD. PLEODIAL-I is a pilot phase IIa study to assess the safety and preliminary evidence of efficacy on cognitive impairment and function of PXT864 in patients with mild AD. PXT864 was taken in single blind during 4 weeks, followed by placebo during 4 weeks, and then PXT864 during 4 last weeks. With this challenge/de-challenge/re-challenge original design, two doses of PXT864 were tested by two sets of patients. Efficacy was assessed through the 11-item Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog). In one of the 6 participating investigational centers, a sub-study was added to assess also PXT864 efficacy with the ERP method. Recordings were performed on Cz, Fz, and Pz at baseline (V1, before first drug administration) and at each 4-week visit (V2, V3, and V4). 3 patients under the lower dose and 3 under the higher dose of PXT864 had completed their 4-visit ERP sessions. An improvement during the 2 periods under active drug, and a worsening during the placebo period were observed in all cases in terms of latencies and amplitudes of P3b on Cz, Fz, and Pz for both doses tested. This expected "challenge, de-challenge, re-challenge" pattern was also found in a spatio-temporal principal component analysis performed on ERP raw data. These ERP results show first evidence of PXT864 neurophysiological activity to restore the balance between glutamate and GABA signaling disrupted by toxic Aß oligomeric peptides, which seemed also to be coupled to a global cognitive improvement in 4-week treatment periods.

Related Topics

Concepts

Neurophysiology Event-related potential Disease Cognition Psychology Neuroscience Medicine Audiology Internal medicine

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1016/j.jalz.2016.06.2216
PDF: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216
OA Status: bronze
Cited By: 2
Related Works: 10
OpenAlex ID: https://openalex.org/W2532739215

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W2532739215

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1016/j.jalz.2016.06.2216

Digital Object Identifier
Title: P4‐125: Cognitive Event‐Related Potentials Used As Biomarkers in Pleodial‐I Study: First Evidence of a Neurophysiological Effect of PXT864 in Mild Alzheimer’s Disease Patients

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2016

Year of publication
Publication date: 2016-07-01

Full publication date if available
Authors: Karim Bennys, Raphaël Haddad, Catherine Scart Grès, Peter A. Schmitt, Jacques Touchon

List of authors in order
Landing page: https://doi.org/10.1016/j.jalz.2016.06.2216

Publisher landing page
PDF URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: bronze

Open access status per OpenAlex
OA URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216

Direct OA link when available
Concepts: Neurophysiology, Event-related potential, Disease, Cognition, Psychology, Neuroscience, Medicine, Audiology, Internal medicine

Top concepts (fields/topics) attached by OpenAlex
Cited by: 2

Total citation count in OpenAlex
Citations by year (recent): 2018: 1, 2017: 1

Per-year citation counts (last 5 years)
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W2532739215
doi	https://doi.org/10.1016/j.jalz.2016.06.2216
ids.doi	https://doi.org/10.1016/j.jalz.2016.06.2216
ids.mag	2532739215
ids.openalex	https://openalex.org/W2532739215
fwci	0.40371701
type	article
title	P4‐125: Cognitive Event‐Related Potentials Used As Biomarkers in Pleodial‐I Study: First Evidence of a Neurophysiological Effect of PXT864 in Mild Alzheimer’s Disease Patients
biblio.issue	7S_Part_22
biblio.volume	12
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T12267
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.2919999957084656
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2737
topics[0].subfield.display_name	Physiology
topics[0].display_name	Diet and metabolism studies
is_xpac	False
apc_list.value	4000
apc_list.currency	USD
apc_list.value_usd	4000
apc_paid
concepts[0].id	https://openalex.org/C152478114
concepts[0].level	2
concepts[0].score	0.660116970539093
concepts[0].wikidata	https://www.wikidata.org/wiki/Q660910
concepts[0].display_name	Neurophysiology
concepts[1].id	https://openalex.org/C67359045
concepts[1].level	3
concepts[1].score	0.6181487441062927
concepts[1].wikidata	https://www.wikidata.org/wiki/Q14026181
concepts[1].display_name	Event-related potential
concepts[2].id	https://openalex.org/C2779134260
concepts[2].level	2
concepts[2].score	0.6029728651046753
concepts[2].wikidata	https://www.wikidata.org/wiki/Q12136
concepts[2].display_name	Disease
concepts[3].id	https://openalex.org/C169900460
concepts[3].level	2
concepts[3].score	0.5766055583953857
concepts[3].wikidata	https://www.wikidata.org/wiki/Q2200417
concepts[3].display_name	Cognition
concepts[4].id	https://openalex.org/C15744967
concepts[4].level	0
concepts[4].score	0.4366616904735565
concepts[4].wikidata	https://www.wikidata.org/wiki/Q9418
concepts[4].display_name	Psychology
concepts[5].id	https://openalex.org/C169760540
concepts[5].level	1
concepts[5].score	0.42870795726776123
concepts[5].wikidata	https://www.wikidata.org/wiki/Q207011
concepts[5].display_name	Neuroscience
concepts[6].id	https://openalex.org/C71924100
concepts[6].level	0
concepts[6].score	0.4282621145248413
concepts[6].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[6].display_name	Medicine
concepts[7].id	https://openalex.org/C548259974
concepts[7].level	1
concepts[7].score	0.36174845695495605
concepts[7].wikidata	https://www.wikidata.org/wiki/Q569965
concepts[7].display_name	Audiology
concepts[8].id	https://openalex.org/C126322002
concepts[8].level	1
concepts[8].score	0.183018296957016
concepts[8].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[8].display_name	Internal medicine
keywords[0].id	https://openalex.org/keywords/neurophysiology
keywords[0].score	0.660116970539093
keywords[0].display_name	Neurophysiology
keywords[1].id	https://openalex.org/keywords/event-related-potential
keywords[1].score	0.6181487441062927
keywords[1].display_name	Event-related potential
keywords[2].id	https://openalex.org/keywords/disease
keywords[2].score	0.6029728651046753
keywords[2].display_name	Disease
keywords[3].id	https://openalex.org/keywords/cognition
keywords[3].score	0.5766055583953857
keywords[3].display_name	Cognition
keywords[4].id	https://openalex.org/keywords/psychology
keywords[4].score	0.4366616904735565
keywords[4].display_name	Psychology
keywords[5].id	https://openalex.org/keywords/neuroscience
keywords[5].score	0.42870795726776123
keywords[5].display_name	Neuroscience
keywords[6].id	https://openalex.org/keywords/medicine
keywords[6].score	0.4282621145248413
keywords[6].display_name	Medicine
keywords[7].id	https://openalex.org/keywords/audiology
keywords[7].score	0.36174845695495605
keywords[7].display_name	Audiology
keywords[8].id	https://openalex.org/keywords/internal-medicine
keywords[8].score	0.183018296957016
keywords[8].display_name	Internal medicine
language	en
locations[0].id	doi:10.1016/j.jalz.2016.06.2216
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S108427512
locations[0].source.issn	1552-5260, 1552-5279
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	1552-5260
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Alzheimer s & Dementia
locations[0].source.host_organization	https://openalex.org/P4310320595
locations[0].source.host_organization_name	Wiley
locations[0].source.host_organization_lineage	https://openalex.org/P4310320595
locations[0].license
locations[0].pdf_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Alzheimer's & Dementia
locations[0].landing_page_url	https://doi.org/10.1016/j.jalz.2016.06.2216
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5067382402
authorships[0].author.orcid	https://orcid.org/0000-0003-1363-0143
authorships[0].author.display_name	Karim Bennys
authorships[0].countries	FR
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210112060
authorships[0].affiliations[0].raw_affiliation_string	Memory Resources and Research Center, CHRU Gui de Chauliac, Montpellier, France
authorships[0].institutions[0].id	https://openalex.org/I4210112060
authorships[0].institutions[0].ror	https://ror.org/02w35z347
authorships[0].institutions[0].type	healthcare
authorships[0].institutions[0].lineage	https://openalex.org/I4210112060
authorships[0].institutions[0].country_code	FR
authorships[0].institutions[0].display_name	Hôpital Gui de Chauliac
authorships[0].author_position	first
authorships[0].raw_author_name	Karim Bennys
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Memory Resources and Research Center, CHRU Gui de Chauliac, Montpellier, France
authorships[1].author.id	https://openalex.org/A5104051888
authorships[1].author.orcid
authorships[1].author.display_name	Raphaël Haddad
authorships[1].countries	FR
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210128706
authorships[1].affiliations[0].raw_affiliation_string	Pharnext SAS, Issy les Moulineaux, France, Paris, France
authorships[1].institutions[0].id	https://openalex.org/I4210128706
authorships[1].institutions[0].ror	https://ror.org/031jemm23
authorships[1].institutions[0].type	company
authorships[1].institutions[0].lineage	https://openalex.org/I4210128706
authorships[1].institutions[0].country_code	FR
authorships[1].institutions[0].display_name	Pharnext (France)
authorships[1].author_position	middle
authorships[1].raw_author_name	Raphael Haddad
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Pharnext SAS, Issy les Moulineaux, France, Paris, France
authorships[2].author.id	https://openalex.org/A5062458629
authorships[2].author.orcid
authorships[2].author.display_name	Catherine Scart Grès
authorships[2].countries	FR
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210128706
authorships[2].affiliations[0].raw_affiliation_string	Pharnext SAS, Issy les Moulineaux, France, Paris, France
authorships[2].institutions[0].id	https://openalex.org/I4210128706
authorships[2].institutions[0].ror	https://ror.org/031jemm23
authorships[2].institutions[0].type	company
authorships[2].institutions[0].lineage	https://openalex.org/I4210128706
authorships[2].institutions[0].country_code	FR
authorships[2].institutions[0].display_name	Pharnext (France)
authorships[2].author_position	middle
authorships[2].raw_author_name	Catherine Scart Gres
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Pharnext SAS, Issy les Moulineaux, France, Paris, France
authorships[3].author.id	https://openalex.org/A5108649545
authorships[3].author.orcid
authorships[3].author.display_name	Peter A. Schmitt
authorships[3].countries	FR
authorships[3].affiliations[0].institution_ids	https://openalex.org/I4210128706
authorships[3].affiliations[0].raw_affiliation_string	Pharnext, Paris, France
authorships[3].institutions[0].id	https://openalex.org/I4210128706
authorships[3].institutions[0].ror	https://ror.org/031jemm23
authorships[3].institutions[0].type	company
authorships[3].institutions[0].lineage	https://openalex.org/I4210128706
authorships[3].institutions[0].country_code	FR
authorships[3].institutions[0].display_name	Pharnext (France)
authorships[3].author_position	middle
authorships[3].raw_author_name	Peter Schmitt
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Pharnext, Paris, France
authorships[4].author.id	https://openalex.org/A5107599697
authorships[4].author.orcid
authorships[4].author.display_name	Jacques Touchon
authorships[4].countries	FR
authorships[4].affiliations[0].institution_ids	https://openalex.org/I4210093292
authorships[4].affiliations[0].raw_affiliation_string	Memory Research Resource Center for Alzheimer's disease, University Hospital Montpellier, France, Montpellier, France
authorships[4].institutions[0].id	https://openalex.org/I4210093292
authorships[4].institutions[0].ror	https://ror.org/00mthsf17
authorships[4].institutions[0].type	healthcare
authorships[4].institutions[0].lineage	https://openalex.org/I4210093292
authorships[4].institutions[0].country_code	FR
authorships[4].institutions[0].display_name	Centre Hospitalier Universitaire de Montpellier
authorships[4].author_position	last
authorships[4].raw_author_name	Jacques Touchon
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Memory Research Resource Center for Alzheimer's disease, University Hospital Montpellier, France, Montpellier, France
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216
open_access.oa_status	bronze
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	P4‐125: Cognitive Event‐Related Potentials Used As Biomarkers in Pleodial‐I Study: First Evidence of a Neurophysiological Effect of PXT864 in Mild Alzheimer’s Disease Patients
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T12267
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.2919999957084656
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2737
primary_topic.subfield.display_name	Physiology
primary_topic.display_name	Diet and metabolism studies
related_works	https://openalex.org/W2915014248, https://openalex.org/W2158956744, https://openalex.org/W63251931, https://openalex.org/W4205472207, https://openalex.org/W2000673263, https://openalex.org/W2094578634, https://openalex.org/W4310675391, https://openalex.org/W2974389624, https://openalex.org/W2391153736, https://openalex.org/W2062033738
cited_by_count	2
counts_by_year[0].year	2018
counts_by_year[0].cited_by_count	1
counts_by_year[1].year	2017
counts_by_year[1].cited_by_count	1
locations_count	1
best_oa_location.id	doi:10.1016/j.jalz.2016.06.2216
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S108427512
best_oa_location.source.issn	1552-5260, 1552-5279
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	1552-5260
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Alzheimer s & Dementia
best_oa_location.source.host_organization	https://openalex.org/P4310320595
best_oa_location.source.host_organization_name	Wiley
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320595
best_oa_location.license
best_oa_location.pdf_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Alzheimer's & Dementia
best_oa_location.landing_page_url	https://doi.org/10.1016/j.jalz.2016.06.2216
primary_location.id	doi:10.1016/j.jalz.2016.06.2216
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S108427512
primary_location.source.issn	1552-5260, 1552-5279
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	1552-5260
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Alzheimer s & Dementia
primary_location.source.host_organization	https://openalex.org/P4310320595
primary_location.source.host_organization_name	Wiley
primary_location.source.host_organization_lineage	https://openalex.org/P4310320595
primary_location.license
primary_location.pdf_url	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2016.06.2216
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Alzheimer's & Dementia
primary_location.landing_page_url	https://doi.org/10.1016/j.jalz.2016.06.2216
publication_date	2016-07-01
publication_year	2016
referenced_works_count	0
abstract_inverted_index.2	219
abstract_inverted_index.3	195, 202
abstract_inverted_index.4	106, 112, 118
abstract_inverted_index.6	154
abstract_inverted_index.a	6, 29, 73, 158, 225, 263, 305
abstract_inverted_index.AD	38
abstract_inverted_index.An	215
abstract_inverted_index.In	150
abstract_inverted_index.Pz	178, 248
abstract_inverted_index.We	21
abstract_inverted_index.an	45
abstract_inverted_index.at	179, 187
abstract_inverted_index.be	302
abstract_inverted_index.by	109, 132, 293
abstract_inverted_index.in	28, 36, 64, 94, 102, 233, 236, 262, 309
abstract_inverted_index.is	5, 72
abstract_inverted_index.of	12, 26, 43, 49, 52, 61, 69, 85, 92, 128, 135, 152, 207, 238, 242, 279
abstract_inverted_index.on	87, 174, 244, 269
abstract_inverted_index.to	34, 78, 162, 283, 301, 304
abstract_inverted_index.AD.	70, 98
abstract_inverted_index.Aß	295
abstract_inverted_index.Cz,	175, 245
abstract_inverted_index.ERP	27, 169, 213, 270, 274
abstract_inverted_index.Fz,	176, 246
abstract_inverted_index.IIa	31, 76
abstract_inverted_index.P3b	243
abstract_inverted_index.V3,	192
abstract_inverted_index.all	234
abstract_inverted_index.and	54, 66, 82, 90, 114, 177, 186, 193, 201, 224, 240, 247, 289
abstract_inverted_index.for	9, 249
abstract_inverted_index.had	209
abstract_inverted_index.has	57
abstract_inverted_index.low	50
abstract_inverted_index.one	151
abstract_inverted_index.raw	271
abstract_inverted_index.the	10, 18, 24, 40, 80, 141, 153, 168, 198, 204, 218, 228, 285
abstract_inverted_index.two	126, 133
abstract_inverted_index.use	25
abstract_inverted_index.was	100, 138, 160, 259
abstract_inverted_index.(V1,	181
abstract_inverted_index.(V2,	191
abstract_inverted_index.GABA	290
abstract_inverted_index.This	253
abstract_inverted_index.V4).	194
abstract_inverted_index.With	121
abstract_inverted_index.also	164, 260, 300
abstract_inverted_index.both	250
abstract_inverted_index.dose	200, 206
abstract_inverted_index.drug	184
abstract_inverted_index.each	188
abstract_inverted_index.even	16
abstract_inverted_index.from	17
abstract_inverted_index.here	23
abstract_inverted_index.last	119
abstract_inverted_index.mild	37, 97
abstract_inverted_index.sets	134
abstract_inverted_index.show	276
abstract_inverted_index.then	115
abstract_inverted_index.this	122
abstract_inverted_index.were	130, 172, 231
abstract_inverted_index.with	96, 167
abstract_inverted_index.(AD),	15
abstract_inverted_index.(ERP)	4
abstract_inverted_index.Scale	146
abstract_inverted_index.These	273
abstract_inverted_index.added	161
abstract_inverted_index.blind	104
abstract_inverted_index.cases	235
abstract_inverted_index.data.	272
abstract_inverted_index.doses	51, 127, 251
abstract_inverted_index.drug,	223
abstract_inverted_index.event	1
abstract_inverted_index.first	183, 277
abstract_inverted_index.fixed	47
abstract_inverted_index.found	261
abstract_inverted_index.lower	199
abstract_inverted_index.phase	30, 75
abstract_inverted_index.pilot	74
abstract_inverted_index.shown	58
abstract_inverted_index.study	33, 77
abstract_inverted_index.taken	101
abstract_inverted_index.terms	237
abstract_inverted_index.their	211
abstract_inverted_index.toxic	294
abstract_inverted_index.under	197, 203, 221
abstract_inverted_index.visit	190
abstract_inverted_index.which	56, 298
abstract_inverted_index.4-week	189, 310
abstract_inverted_index.PXT864	93, 99, 116, 129, 165, 208, 280
abstract_inverted_index.active	222
abstract_inverted_index.animal	67
abstract_inverted_index.assess	79, 163
abstract_inverted_index.before	182
abstract_inverted_index.during	105, 111, 117, 217, 227
abstract_inverted_index.effect	42
abstract_inverted_index.global	306
abstract_inverted_index.higher	205
abstract_inverted_index.models	68
abstract_inverted_index.period	230
abstract_inverted_index.report	22
abstract_inverted_index.safety	81
abstract_inverted_index.seemed	299
abstract_inverted_index.single	103
abstract_inverted_index.stage.	20
abstract_inverted_index.tested	131
abstract_inverted_index.weeks,	107, 113
abstract_inverted_index.weeks.	120
abstract_inverted_index.11-item	142
abstract_inverted_index.4-visit	212
abstract_inverted_index.Disease	14, 144
abstract_inverted_index.PXT864,	44
abstract_inverted_index.balance	286
abstract_inverted_index.between	287
abstract_inverted_index.coupled	303
abstract_inverted_index.design,	125
abstract_inverted_index.explore	35
abstract_inverted_index.method.	170
abstract_inverted_index.pattern	258
abstract_inverted_index.periods	220
abstract_inverted_index.placebo	110, 229
abstract_inverted_index.related	2
abstract_inverted_index.restore	284
abstract_inverted_index.results	275
abstract_inverted_index.tested.	252
abstract_inverted_index.through	140
abstract_inverted_index.usefull	7
abstract_inverted_index.Efficacy	137
abstract_inverted_index.activity	282
abstract_inverted_index.analysis	267
abstract_inverted_index.assessed	139
abstract_inverted_index.baseline	180
abstract_inverted_index.cellular	65
abstract_inverted_index.centers,	157
abstract_inverted_index.clinical	32
abstract_inverted_index.efficacy	86, 166
abstract_inverted_index.evidence	84, 278
abstract_inverted_index.expected	254
abstract_inverted_index.followed	108
abstract_inverted_index.function	91
abstract_inverted_index.multiple	59
abstract_inverted_index.observed	232
abstract_inverted_index.original	124
abstract_inverted_index.patients	39, 95, 196
abstract_inverted_index.periods.	312
abstract_inverted_index.subscale	148
abstract_inverted_index.Cognitive	0
abstract_inverted_index.baclofen,	55
abstract_inverted_index.biomarker	8
abstract_inverted_index.cognitive	88, 147, 307
abstract_inverted_index.completed	210
abstract_inverted_index.component	266
abstract_inverted_index.diagnosis	11
abstract_inverted_index.disrupted	292
abstract_inverted_index.glutamate	288
abstract_inverted_index.latencies	239
abstract_inverted_index.patients.	136
abstract_inverted_index.peptides,	297
abstract_inverted_index.performed	173, 268
abstract_inverted_index.potential	3
abstract_inverted_index.principal	265
abstract_inverted_index.sessions.	214
abstract_inverted_index.signaling	291
abstract_inverted_index.sub-study	159
abstract_inverted_index.treatment	311
abstract_inverted_index.worsening	226
abstract_inverted_index.Assessment	145
abstract_inverted_index.PLEODIAL-I	71
abstract_inverted_index.Recordings	171
abstract_inverted_index.alteration	63
abstract_inverted_index.amplitudes	241
abstract_inverted_index.impairment	89
abstract_inverted_index.oligomeric	296
abstract_inverted_index.reversions	60
abstract_inverted_index."challenge,	255
abstract_inverted_index.(ADAS-Cog).	149
abstract_inverted_index.Alzheimer's	13, 143
abstract_inverted_index.acamprosate	53
abstract_inverted_index.combination	48
abstract_inverted_index.improvement	216, 308
abstract_inverted_index.preclinical	19
abstract_inverted_index.preliminary	83
abstract_inverted_index.symptomatic	41
abstract_inverted_index.pathological	62
abstract_inverted_index.de-challenge,	256
abstract_inverted_index.participating	155
abstract_inverted_index.re-challenge"	257
abstract_inverted_index.administration)	185
abstract_inverted_index.investigational	156
abstract_inverted_index.spatio-temporal	264
abstract_inverted_index.under-development	46
abstract_inverted_index.neurophysiological	281
abstract_inverted_index.challenge/de-challenge/re-challenge	123
cited_by_percentile_year.max	94
cited_by_percentile_year.min	90
countries_distinct_count	1
institutions_distinct_count	5
citation_normalized_percentile.value	0.69473699
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False